Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 1—February 2001

Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease: Background, Evolution, and Current Concerns

Paul Brown*Comments to Author , Robert G. Will†, Raymond Bradley‡, David M. Asher§, and Linda Detwiler¶
Author affiliations: *National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA; †National Creutzfeldt-Jakob Disease Surveillance Unit, Western General Hospital, Edinburgh, Scotland; ‡Central Veterinary Laboratory, New Haw, Addlestone, UK; §Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA; ¶Animal and Plant Health Inspection Service, U.S. Department of Agriculture, Robbinsville, New Jersey, USA

Main Article

Table 3

Chronology of variant Creutzfeld-Jakob disease (vCJD) in the United Kingdom and other European countries, as of December 2000

Year of onset United Kingdom France Ireland
1994 8 1
1995 10
1996 11
1997 14
1998 17
1999a 20 (+4) 1 (+1) 1
2000a 1 (+2)

aParentheses indicate still-living persons with probable vCJD or deceased persons whose diagnoses have not yet been confirmed by neuropathologic examination. In 2000, additional cases have been identified that do not yet meet the minimum clinical criteria for a premortem diagnosis of "probable" vCJD. Dates are for year of onset of illness, not year of death.

Main Article

Page created: March 23, 2011
Page updated: August 07, 2012
Page reviewed: August 07, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.